Skip to main content
Premium Trial:

Request an Annual Quote

PPO Three Rivers to Cover BioTheranostics' Cancer Testing Services

NEW YORK (GenomeWeb News) – Cancer diagnostics services firm BioTheranostics today announced a contract with preferred provider organization Three Rivers Provider Network.

The contract covers the San Diego firm's testing services, including CancerType ID for diagnosing metastatic cancer, and Breast Cancer Index for predicting the risks of recurrence of early stage, estrogen receptor-positive breast cancer. The agreement makes BioTheranostics' tests available to an additional 15 million covered lives in the US, the firm said.

BioTheranostics CEO Richard Ding said that the deal with Three Rivers brings the total number of covered lives in the US under contract for CancerType ID to 91 million.

The company said in August that it received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more